ADM: A Longstanding Dividend Payer in the Agriculture Sector
Archer-Daniels-Midland Company (NYSE:ADM) is one of the Best Dividend Leaders to Buy Now.
The company is undertaking a strategic plan focused on boosting profitability, targeting $200–$300 million in cost savings over the next few years through operational streamlining and workforce reductions. These steps are designed to strengthen margins and bolster financial stability amid persistent economic headwinds.
A wheat field at sunset, showing the company's commitment to agricultural commodities.
This initiative may also support Archer-Daniels-Midland Company (NYSE:ADM)'s dividend. The company has raised its dividend annually for 52 consecutive years and has maintained uninterrupted quarterly payouts for 90 years. Strong underlying business fundamentals further back the stability of its dividend. At the end of the most recent quarter, the company had over $864 million available in cash and cash equivalents. It currently offers a quarterly dividend of $0.51 per share and has a dividend yield of 3.86%, as of June 23.
Archer-Daniels-Midland Company (NYSE:ADM) plays a vital role in the global agricultural supply chain, helping ensure food security by linking local demands with worldwide resources and capabilities.
While we acknowledge the potential of ADM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: and .
Disclosure. None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Kevin Durant's Calculated Control Over His Trade to Rockets
Kevin Durant's Calculated Control Over His Trade to Rockets originally appeared on Athlon Sports. Kevin Durant's move to the Houston Rockets was not just a trade; it was a meticulously orchestrated process where Durant himself wielded significant influence. Advertisement According to ESPN's Brian Windhorst, Rockets head coach Ime Udoka actively pushed for the acquisition, but Durant's strategic decisions were pivotal. He repeatedly declined trade packages from teams like the Golden State Warriors and Minnesota Timberwolves, waiting for the right moment and price. This patience paid off when the Phoenix Suns, unable to secure a better deal, agreed to a surprisingly low offer from Houston, involving Jalen Green, Dillon Brooks, and future draft picks. The Rockets were able to retain Reed Sheppard, Tari Eason, Cam Whittmore, and Jabari Smith Jr., all intriguing young assets that can develop greatly in the coming years. Advertisement Durant's control over his destination was evident as he rejected potential trades, ensuring he landed where he wanted. Former Phoenix Suns forward Kevin DurantRick Scuteri-Imagn Images His relationship with Udoka, forged during their time together with the Brooklyn Nets and with USA Basketball, likely played a role in his preference for Houston. The Rockets, in turn, capitalized on Durant's leverage, acquiring a superstar at a bargain. This move not only elevates Houston's roster but also highlights Durant's ability to shape his career path. The Rockets, who immediately become championship contenders with the addition of Durant, will look to get the ball rolling early next season as Durant's championship window is shrinking. Advertisement The trade, announced on Sunday, underscores Durant's strategic acumen and the Rockets' opportunistic approach, setting the stage for an intriguing new chapter in the NBA. Related: Kevin Durant's True Feelings on Rockets Trade Revealed This story was originally reported by Athlon Sports on Jun 23, 2025, where it first appeared.
Yahoo
31 minutes ago
- Yahoo
How Is Incyte's Stock Performance Compared to Other Biotech Stocks?
With a market cap of $13.3 billion, Incyte Corporation (INCY) is a global biopharmaceutical company focused on discovering, developing, and commercializing therapies in oncology, inflammation, and autoimmunity. The Wilmington, Delaware-based company has over 2,600 employees and a manufacturing and R&D footprint across North America, Europe, and Asia. Companies valued at $10 billion or more are generally labelled as 'large-cap' stocks, and Incyte fits this criterion perfectly. Its leadership stems from its strong portfolio of high-demand specialty drugs, notably Jakafi and Opzelura, which serve as key revenue drivers in the oncology and dermatology markets. Its robust research and development capabilities, with a diverse and advancing pipeline targeting cancer, inflammation, and autoimmune diseases, position it for long-term innovation. The Next Trillion-Dollar Boom? 3 Stocks to Buy with 300 Million Humanoid Robots on the Horizon. Warren Buffett's Berkshire Hathaway Now Pays 5% of All Corporate Income Taxes in America Meta's Mark Zuckerberg Says the Technology They're Developing Will 'See What You See and Hear What You Hear' Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Despite that, INCY has fallen 19.9% from its 52-week high of $83.95, achieved on Nov. 8. Yet, shares of INCY have risen 8.6% over the past three months, compared to the SPDR S&P Biotech ETF's (XBI) 5.6% fall during the same time frame. INCY is down 2.6% on a YTD basis, lagging behind XBI's 8.7% gains. However, shares of Incyte have climbed 6.4% over the past 52 weeks, compared to XBI's 10.9% fall over the same time frame. INCY has been trading above its 200-day moving average since early June and has mostly stayed above its 50-day moving average since mid-May. On June 16, shares of Incyte rose more than 4% following the announcement of encouraging clinical trial results for its investigational therapy targeting a blood disorder. The company reported positive data from two separate studies, which demonstrated the treatment's potential effectiveness and safety in managing the condition, likely a form of myeloproliferative neoplasm or a related hematologic disease. The strong outcomes from these trials bolstered investor confidence in the strength of Incyte's R&D pipeline and its ability to diversify beyond its flagship drug, Jakafi. In comparison, rival Exelixis, Inc. (EXEL) outperformed INCY. Shares of Exelixis have gained 95.4% over the past 52 weeks and 30.2% on a YTD basis. Among the 25 analysts covering the stock, there is a consensus rating of 'Moderate Buy,' and its mean price target of $75.81 indicates an upswing potential of 12.7% from the prevailing price levels. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
E&E News
31 minutes ago
- E&E News
House appropriators to advance more fiscal 2026 bills
House appropriators will pick up where they left off before last week's recess with a vote on their Agriculture proposal and a flurry of markups for other bills. The full House will also vote on its first fiscal 2026 spending bill: Republicans' Military Construction-Veterans Affairs plan. The Appropriations Committee has postponed its release of the Interior-Environment bill while the panel catches up on previously scheduled markups that were derailed by a former lawmaker's funeral and other events earlier this month. Democrats are also introducing numerous amendments, forcing markups to go long. Advertisement Chair Tom Cole (R-Okla.) is pursuing an aggressive markup schedule with the hope of getting all 12 fiscal 2026 spending bills across the House floor later this summer.
